Biotinylated Human B7-H6 / NCR3LG1 Protein, Fc,Avitag™
| Specifications | |
|---|---|
| Category: | MABSol® Biotin Labeled Proteins |
| Molecular Weight: | 54.8 kDa |
| Tag: | C-Fc & C-Avi |
| Label / Conjugate: | Biotin-labeled |
| Source: | Biotinylated Human B7-H6, Fc,Avitag (B76-H82Wb) is expressed from human 293 cells (HEK293). It contains AA Asp 25 - Ser 262 (Accession # Q68D85-1). |
| Purity: | 95% |
| Endotoxin Level: | 1.0 EU per μg |
| Format: | Powder |
| Additional Information | |
|---|---|
| Synonyms: | B7-H6,NCR3LG1,B7 Homolog 6 |
| Organism: | Human |
| Accn. No.: | Q68D85-1 |
Sequence Information
Asp 25 - Ser 262
Background
The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene; however, many B7H6 genes were detected in a single large cluster in the Xenopus genome. Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.
Price
495,00 €
